Vmbook Online ordering
Gilead Sciences Inc
I am able to provide some general information about the biotechnology company with the stock ticker GILD, which stands for Gilead Sciences, Inc. I am an AI language model, and my knowledge is based on the data available up to the time I was last trained, so for the most up-to-date information, please refer to Gilead Sciences' official website or financial statements.
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in various areas, including virology, inflammation, and oncology. The company is headquartered in Foster City, California, USA.
Here are some key points about Gilead Sciences, focusing on its stock performance and financials:
1. Stock Performance:
Gilead Sciences' stock price has experienced fluctuation over the years. Historical performance may vary, but for reference, as of 2021:
* The 52-week high was approximately $75.59 per share, and the 52-week low was around $57.94 per share.
2. Earnings and Financial Metrics:
Gilead Sciences has reported earnings and financial metrics over the years, though these figures change over time. Here are some historical values for reference:
* Revenue (in millions):
+ 2018: $22.13 billion
+ 2019: $22.44 billion
+ 2020 (YTD): $21.76 billion
* Net Income (in millions):
+ 2018: $5.50 billion
+ 2019: $6.04 billion
+ 2020 (YTD): $5.12 billion
* Earnings Per Share (EPS):
+ 2018: $4.14
+ 2019: $4.70
+ 2020 (YTD): $3.77
3. Dividends:
Gilead Sciences pays dividends to shareholders. The dividend amount may fluctuate over time. As of 2021, the annual dividend is $2.48 per share.
4. Market Capitalization and Other Metrics:
* As of 2021, Gilead Sciences' market capitalization is approximately $66.48 billion.
* The Price-to-Earnings (P/E) ratio, which measures the stock price relative to its earnings per share (EPS), varies over time. The P/E ratio helps investors evaluate the relative value of a company's shares by comparing the stock price with its earnings. A lower P/E ratio suggests that a stock is undervalued, while a higher P/E ratio implies that it might be overpriced. As of 2021, Gilead Sciences' P/E ratio is approximately 17.65.
This information is for general purposes only and should not be considered financial advice. Always consult a financial advisor or conduct your research when making investment decisions. For the most up-to-date information, visit Gilead Sciences' official website or consult their financial statements.